Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1

Erol, Çetin

doi:10.14744/AnatolJCardiol.2026.8

Editorial

Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1

Çetin Erol ¹

¹Department of Cardiology, Ankara University Faculty of Medicine, İbn-i Sina Hospital; Ankara, Türkiye

Anatol J Cardiol 2026; 30(8): 486-486 PubMed ID: 42504904 DOI: 10.14744/AnatolJCardiol.2026.8

Full Text PDF

Erol Ç. Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1. Anatol J Cardiol. 2026 ;30(8):486-486. doi: 10.14744/AnatolJCardiol.2026.8.

Erol Ç. Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1. Anatol J Cardiol. 2026;30(8):486-486. doi: 10.14744/AnatolJCardiol.2026.8

Erol, Ç. (2026). Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1. The Anatolian Journal of Cardiology, 30(8), 486-486. https://doi.org/10.14744/AnatolJCardiol.2026.8

Erol, Ç.. "Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1." The Anatolian Journal of Cardiology, vol. 30, no. 8, 2026, pp. 486-486. https://doi.org/10.14744/AnatolJCardiol.2026.8.

Erol, Ç.. 2026. "Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1." The Anatolian Journal of Cardiology 30, no. 8: 486-486. https://doi.org/10.14744/AnatolJCardiol.2026.8.

Journal Display Format:

Authors: Çetin Erol
Article Title: Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1
Journal Name: The Anatolian Journal of Cardiology
Year: 2026
Volume: 30
Issue: 8
Pages: 486 - 486
DOI: 10.14744/AnatolJCardiol.2026.8

RIS BibTeX EndNote Medlars